रेटट्रूटाइड पाउडर

Retatrutide Raw Material Manufacturer-YTBIO

रेटट्रूटाइड पाउडर is a novel peptide-based GLP-1/GIP/glucagon triple receptor agonist that synergistically regulates appetite and energy metabolism. Multiple analyses and trials have confirmed that retatrutide significantly reduces weight, blood pressure, glycated hemoglobin, and lipid levels in obese or overweight adults, and shows therapeutic potential in the remission of non-alcoholic fatty liver disease and cardiovascular-renal-metabolic syndrome.

YTBIO supplies retatrutide with a purity of 98%+ (HPLC). We offer flexible MOQ and customized packaging, and provide corresponding COA and other compliance documents. All production processes adhere to cGMP standards, ensuring high batch-to-batch consistency. Please contact us at any time for the latest quotation and related technical information.

YTBIO क्यों चुनें?

·YTBIO has long focused on functional raw materials and innovative active ingredients, boasting over 12 years of experience serving the international market.

·With our own production and supply system, YTBIO provides customers with more stable quality and cost-effectiveness.

·Our products are sold to multiple countries and regions, adaptable to the diverse needs of different markets in terms of documentation, packaging, and collaboration.

·We support customized packaging and flexible minimum order quantities to meet various development requirements.

·We can provide COA, specification sheets, test reports, and other relevant documents to help you improve procurement and project progress efficiency.

जाँच रिपोर्ट

What Is Its Mechanism Of Action?

1. Activates GLP-1 receptor
· Promotes insulin secretion
· Inhibits glucagon release
· Delays gastric emptying
· Centrally inhibits appetite

2. Activates GIP receptor
· Synergistically promotes insulin secretion
· Improves insulin sensitivity

3. Activates glucagon receptor
· Increases energy expenditure
· Reduces fat without significantly increasing blood sugar

संभावित स्वास्थ्य लाभ

महत्वपूर्ण वजन घटाने: Average weight loss of 24% over 48 weeks in clinical trials

Powerful blood sugar control: Lowers glycated hemoglobin, effective for type 2 diabetes.

Improved cardiovascular metabolism: Can lower blood pressure and blood lipids, reduce liver fat content, beneficial for non-alcoholic fatty liver disease.

Experiment On Weight Loss With Retatrutide

सामान्य तौर पर, ग्लूकागन-जैसे पेप्टाइड-1 रिसेप्टर एगोनिस्ट (GLP-1A) प्रकार की वजन घटाने वाली दवाएँ, जिन्हें लिराग्लूटाइड इंजेक्शन और सेमाग्लूटाइड इंजेक्शन द्वारा दर्शाया जाता है, एक वर्ष की अनुवर्ती अवधि के दौरान शरीर के वजन को लगभग 8% या 17% तक कम कर सकती हैं, जबकि वर्तमान बेरियाट्रिक सर्जरी (गैस्ट्रिक वॉल्यूम रिडक्शन सर्जरी) का वजन घटाने का प्रभाव भी लगभग 30% है। हाल ही में लॉन्च किया गया रेटाट्रुटाइड तीन हार्मोन रिसेप्टर्स का एक संयुक्त एगोनिस्ट है, अर्थात्, ग्लूकागन-जैसे पेप्टाइड-1 रिसेप्टर (GLP-1), ग्लूकोज-निर्भर इंसुलिनोट्रोपिक पॉलीपेप्टाइड रिसेप्टर (GIP), और ग्लूकागन रिसेप्टर (GCG)। क्या यह दवा अधिक स्पष्ट वजन घटाने के प्रभाव ला सकती है? हाल ही में, NEJM पत्रिका ने रेटाट्रुटाइड चरण II नैदानिक ​​​​अध्ययन के परिणाम प्रकाशित किए।

In this phase 2, randomized, controlled, double-blind clinical trial, the researchers enrolled patients with a body mass index (BMI) >= 30 or BMI >= 27 plus at least one obesity-related disease/abnormality. Participants were randomly assigned in a 2:1:1:1:1:2:2 ratio to receive subcutaneous weekly injections of Retatrutide (1 mg, 4 mg [initial 2 mg], 4 mg [initial 4 mg], 8 mg [initial 2 mg], 8 mg [initial 4 mg], or 12 mg [initial 2 mg]) or placebo for 48 weeks. The primary endpoint was the percentage change in body weight from baseline at 24 weeks. Secondary endpoints included the percentage change in body weight from baseline to 48 weeks, a weight loss of 5% or more, 10% or more, or 15% or more. Drug safety indicators were also evaluated.

The results showed that of the 338 adults recruited, 51.8% were male. The percentage change in body weight at 24 weeks in the Retatrutide Powder group was -7.2% in the 1mg group, -12.9% in the combined 4mg group, -17.3% in the combined 8mg group, and -17.5% in the 12mg group, while it was -1.6% in the placebo group. At 48 weeks of follow-up, the percentage change in body weight in the Retatrutide group was -8.7% in the 1 mg group, -17.1% in the combined 4 mg group, -22.8% in the combined 8 mg group, -24.2% in the 12 mg group, and -2.1% in the placebo group. At 48 weeks, the proportion of patients who lost more than 5%, more than 10%, and more than 15% of their body weight was 92%, 75%, and 60% in the 4 mg Retatrutide group, 100%, 91%, and 75% in the 8 mg Retatrutide group, 100%, 93%, and 83% in the 12 mg Retatrutide group, and 27%, 9%, and 2% in the placebo group. The most common adverse reactions in the Retatrutide group were gastrointestinal symptoms, which occurred in a dose-related manner, were mostly mild to moderate in severity, and were less common in the group starting with low doses such as 2 mg and 4 mg. Heart rate increased in a dose-dependent manner and declined after reaching a peak at 24 weeks.

अनुप्रयोगों

Retatrutide is widely used in peptide research, metabolic health research, drug development, and biotechnology research applications.
 

हमसे संपर्क करें

युआंताई ऑर्गेनिक बायो ग्राहकों को उच्चतम गुणवत्ता प्रदान करने के लिए प्रतिबद्ध है रेटट्रूटाइड पाउडर 98% तक  और सेवाएँ ताकि प्रत्येक उपभोक्ता प्राकृतिक, स्वस्थ और उच्च गुणवत्ता वाले भोजन का आनंद ले सके। यदि हमारे उत्पादों के बारे में आपकी कोई पूछताछ या आवश्यकता है, तो कृपया बेझिझक हमसे संपर्क करें, और हम यथाशीघ्र आपको उत्तर देंगे।मामले में

तेल:86-029-86478251 / 86-029-86119593
Whatsapp: 8617782577059
ईमेल:sales@sxytorganic.com
कार्यालय जोड़ें: नंबर 801, बिल्डिंग 3, दाहुआ शुझी औद्योगिक पार्क, तियांगु 6वीं रोड, यंता जिला, शीआन, शानक्सी, चीन।